The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Bio-Techne Corp (NASDAQ: TECH) closed at $63.82 up 1.38% from its previous closing price of $62.95. In other words, the price has increased by $1.38 from its previous closing price. On the day, 1.77 million shares were traded. TECH stock price reached its highest trading level at $64.725 during the session, while it also had its lowest trading level at $63.105.
Ratios:
For a deeper understanding of Bio-Techne Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 68.60 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 44.38. For the most recent quarter (mrq), Quick Ratio is recorded 2.81 and its Current Ratio is at 4.22. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.19.
On August 21, 2025, Citigroup Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $70.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 25 ’25 when Nusse Roeland sold 17,040 shares for $56.36 per share. The transaction valued at 960,388 led to the insider holds 44,559 shares of the business.
BAUMGARTNER ROBERT V sold 17,040 shares of TECH for $957,818 on Aug 25 ’25. The Director now owns 44,863 shares after completing the transaction at $56.21 per share. On Aug 25 ’25, another insider, ROELAND NUSSE, who serves as the Director of the company, bought 17,040 shares for $56.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TECH now has a Market Capitalization of 9943966720 and an Enterprise Value of 10193477632. As of this moment, Bio-Techne’s Price-to-Earnings (P/E) ratio for their current fiscal year is 130.46, and their Forward P/E ratio for the next fiscal year is 28.88. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 12.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.17 while its Price-to-Book (P/B) ratio in mrq is 5.06. Its current Enterprise Value per Revenue stands at 8.378 whereas that against EBITDA is 32.007.
Stock Price History:
The Beta on a monthly basis for TECH is 1.46, which has changed by -0.14805794 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, TECH has reached a high of $79.28, while it has fallen to a 52-week low of $46.01. The 50-Day Moving Average of the stock is 5.52%, while the 200-Day Moving Average is calculated to be 15.00%.
Shares Statistics:
For the past three months, TECH has traded an average of 2.25M shares per day and 1688610 over the past ten days. A total of 155.75M shares are outstanding, with a floating share count of 153.93M. Insiders hold about 1.21% of the company’s shares, while institutions hold 104.94% stake in the company. Shares short for TECH as of 1763078400 were 9265811 with a Short Ratio of 4.11, compared to 1760486400 on 6939394. Therefore, it implies a Short% of Shares Outstanding of 9265811 and a Short% of Float of 6.79.
Dividends & Splits
According to the company, the forward annual dividend rate for TECH is 0.32, from 0.32 in the trailing year. Against a Trailing Annual Dividend Yield of 0.0050833994. The stock’s 5-year Average Dividend Yield is 0.42. The current Payout Ratio is 69.67% for TECH, which recently paid a dividend on 2025-11-17 with an ex-dividend date of 2025-11-17. Stock splits for the company last occurred on 2022-11-30 when the company split stock in a 4:1 ratio.
Earnings Estimates
The dynamic stock of Bio-Techne Corp (TECH) is currently being evaluated by a team of 12.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.56, with high estimates of $0.6 and low estimates of $0.53.
Analysts are recommending an EPS of between $2.04 and $1.9 for the fiscal current year, implying an average EPS of $1.98. EPS for the following year is $2.2, with 14.0 analysts recommending between $2.32 and $2.01.
Revenue Estimates
A total of 12 analysts believe the company’s revenue will be $290.15M this quarter.It ranges from a high estimate of $297M to a low estimate of $286.8M. As of. The current estimate, Bio-Techne Corp’s year-ago sales were $297.03MFor the next quarter, 12 analysts are estimating revenue of $321.53M. There is a high estimate of $332.2M for the next quarter, whereas the lowest estimate is $314.26M.
A total of 14 analysts have provided revenue estimates for TECH’s current fiscal year. The highest revenue estimate was $1.25B, while the lowest revenue estimate was $1.21B, resulting in an average revenue estimate of $1.22B. In the same quarter a year ago, actual revenue was $1.22BBased on 13 analysts’ estimates, the company’s revenue will be $1.31B in the next fiscal year. The high estimate is $1.34B and the low estimate is $1.28B.
